GMP Adenovirus Vectors Production
Businesses / Posted 6 months ago by Marcia Brady / 41 views
Adenoviral vector-based vaccines are intensively studied because of their potential to prevent infectious diseases for which current vaccines are suboptimal (such as anthrax and influenza vaccines) or for which licensed vaccines are not available (such as malaria and human immunodeficiency virus [HIV]). Once adenovirus vector-based vaccines will be licensed for the prevention of infectious diseases, manufacturing methods capable of reliably delivering large numbers of vaccine doses will be required. The expanding potential commercial product pipeline and the continuously advancing development of recombinant adenoviral vectors for gene therapy require that products are well characterized and consistently manufactured to rigorous tolerances of purity, potency and safety. With the recent increase in biopharmaceutical funding in gene therapy, industry partners are requiring their academic counterparts to meet higher levels of GMP compliance at earlier stages of clinical development.
- Listing ID: 41907
- Country: USA
- City: New York